- Market Capitalization, $K 502,316
- Shares Outstanding, K 88,203
- Annual Sales, $ 143,010 K
- Annual Income, $ -400,420 K
- 60-Month Beta 2.28
- Price/Sales 3.68
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+0.79 (+15.52%)since 08/25/20
| || |
-1.43 (-19.56%)since 06/25/20
| || |
+1.70 (+40.67%)since 09/25/19
The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the data being presented as e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. These include initial data from the...
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that an abstract featuring data from an exploratory analysis of the ARIEL3 clinical study evaluating Rubraca(R) (rucaparib) as maintenance treatment...
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six e-posters highlighting clinical data from the lucitanib and Rubraca(R) (rucaparib) clinical development programs, as well as preclinical data...
"Glioblastoma is the most common and aggressive cancerous brain tumour in adults due to its resistance ...
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on...
SmarTrend identified a Downtrend for Clovis Oncology (NASDAQ:CLVS) on May 20th, 2020 at $7.35. In approximately 4 months, Clovis Oncology has returned 28.23% as of today's recent price of $5.28.
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) approved the FoundationOne(R) Liquid CDx, Foundation Medicine's comprehensive liquid biopsy test for...
, /PRNewswire/ -- Various reports on the global metastatic cancer treatment market all project continued growth in the next several years. One such report from Industry Research says that the global metastatic...